Celldex Therapeutics, Inc. (CLDX) stock
CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$27.55−0.49 (-1.75%)
Close on Nov 18, 2026Market cap $2.16BP/E –Yield –
Celldex Therapeutics shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Celldex Therapeutics's shares outstanding was 78M at Jun 30, 2026. For fiscal 2025 it was 66M, up 3.1% from the year before. Over ten years it grew 26.2% a year on average. The highest annual figure on record is 66M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 66M | +3.1% |
| FY2024 | Dec 31, 2024 | 64M | +32.9% |
| FY2023 | Dec 31, 2023 | 48M | +103229.2% |
| FY2022 | Dec 31, 2022 | 0M | +9.4% |
| FY2021 | Dec 31, 2021 | 0M | +44.6% |
| FY2020 | Dec 31, 2020 | 0M | +104.3% |
| FY2019 | Dec 31, 2019 | 0M | +38.9% |
| FY2018 | Dec 31, 2018 | 0M | -99.9% |
| FY2017 | Dec 31, 2017 | 9M | +26.6% |
| FY2016 | Dec 31, 2016 | 7M | +4.6% |
| FY2015 | Dec 31, 2015 | 6M | +8.6% |
| FY2014 | Dec 31, 2014 | 6M | +12.1% |
| FY2013 | Dec 31, 2013 | 5M | +38.2% |
| FY2012 | Dec 31, 2012 | 4M | +46.1% |
| FY2011 | Dec 31, 2011 | 3M | +24.0% |
| FY2010 | Dec 31, 2010 | 2M | +60.8% |
| FY2009 | Dec 31, 2009 | 1M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 78M | +17.3% |
| Q1 FY2026 | Mar 31, 2026 | 67M | +100310.3% |
| Q3 FY2025 | Sep 30, 2025 | 0M | +0.6% |
| Q2 FY2025 | Jun 30, 2025 | 66M | +112675.4% |
| Q1 FY2025 | Mar 31, 2025 | 66M | +140360.4% |
| Q3 FY2024 | Sep 30, 2024 | 0M | +40.3% |
| Q2 FY2024 | Jun 30, 2024 | 0M | +39.8% |
| Q1 FY2024 | Mar 31, 2024 | 0M | +24.9% |
| Q3 FY2023 | Sep 30, 2023 | 0M | +0.7% |
| Q2 FY2023 | Jun 30, 2023 | 0M | +1.1% |
| Q1 FY2023 | Mar 31, 2023 | 0M | +1.0% |
| Q4 FY2022 | Dec 31, 2022 | 0M | -99.9% |
| Q3 FY2022 | Sep 30, 2022 | 0M | -99.9% |
| Q2 FY2022 | Jun 30, 2022 | 0M | -99.9% |
| Q1 FY2022 | Mar 31, 2022 | 0M | -99.9% |
| Q3 FY2021 | Sep 30, 2021 | 45M | +105.8% |
| Q2 FY2021 | Jun 30, 2021 | 40M | +127.6% |
| Q1 FY2021 | Mar 31, 2021 | 40M | +159.2% |
| Q3 FY2020 | Sep 30, 2020 | 39M | +181.5% |
| Q2 FY2020 | Jun 30, 2020 | 22M | +79.6% |
| Q1 FY2020 | Mar 31, 2020 | 17M | +59.5% |
| Q3 FY2019 | Sep 30, 2019 | 15M | +55.5% |
| Q2 FY2019 | Jun 30, 2019 | 14M | +48.9% |
| Q1 FY2019 | Mar 31, 2019 | 12M | +35.0% |
| Q3 FY2018 | Sep 30, 2018 | 11M | +26.3% |
| Q2 FY2018 | Jun 30, 2018 | 10M | +17.8% |
| Q1 FY2018 | Mar 31, 2018 | 9M | +14.6% |
| Q4 FY2017 | Dec 31, 2017 | 9M | +26.6% |
| Q3 FY2017 | Sep 30, 2017 | 9M | +28.8% |
| Q2 FY2017 | Jun 30, 2017 | 8M | – |
| Q1 FY2017 | Mar 31, 2017 | 8M | – |
| Q4 FY2016 | Dec 31, 2016 | 7M | – |
| Q3 FY2016 | Sep 30, 2016 | 7M | – |
See a number that looks wrong?